Keywords: burroughs, wellcome, stop, marketing, mepron, atovaquone, tablets

Burroughs Wellcome

Article | 22 May 1995

- Burroughs Wellcome is to stop marketing Mepron (atovaquone) tablets for Pneumocystis carinii pneumonia patients intolerant to trimethoprim/sulfamethoxazole, after receiving ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Atovaquone

Mepron

Gantanol

Sulfamethoxazole

Trimethoprim

Go to drug listing